# A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

> **NCT02723994** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 171 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Asparaginase Erwinia Chrysanthemi
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin
- **DRUG:** Leucovorin Calcium
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** Pegaspargase
- **DRUG:** Prednisone
- **DRUG:** Thioguanine
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT02723994
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-30
- **Primary completion:** 2026-03-03
- **Final completion:** 2026-03-03
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02723994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02723994, "A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02723994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*